Can Human Embryonic Stem Cell-Derived Stromal Cells Serve a Starting Material for Myoblasts?

A large number of myocytes is necessary to treat intractable muscular disorders such as Duchenne muscular dystrophy with cell-based therapies. However, starting materials for cellular therapy products such as myoblasts, marrow stromal cells, menstrual blood-derived cells and placenta-derived cells have a limited lifespan and cease to proliferate in vitro. From the viewpoints of manufacturing and quality control, cells with a long lifespan are more suitable as a starting material. In this study, we generated stromal cells for future myoblast therapy from a working cell bank of human embryonic stem cells (ESCs). The ESC-derived CD105+ cells with extensive in vitro proliferation capability exhibited myogenesis and genetic stability in vitro. These results imply that ESC-derived CD105+ cells are another cell source for myoblasts in cell-based therapy for patients with genetic muscular disorders. Since ESCs are immortal, mesenchymal stromal cells generated from ESCs can be manufactured at a large scale in one lot for pharmaceutical purposes.

[1]  F. Zara,et al.  The ubiquitin ligase tripartite-motif-protein 32 is induced in Duchenne muscular dystrophy , 2016, Laboratory Investigation.

[2]  J. Weis,et al.  Activation of osmolyte pathways in inflammatory myopathy and Duchenne muscular dystrophy points to osmoregulation as a contributing pathogenic mechanism , 2016, Laboratory Investigation.

[3]  T. Cantz,et al.  Mesenchymal Stem/Stromal Cells Derived from Induced Pluripotent Stem Cells Support CD34pos Hematopoietic Stem Cell Propagation and Suppress Inflammatory Reaction , 2015, Stem cells international.

[4]  Yilin Cao,et al.  Comparison of immunological characteristics of mesenchymal stem cells derived from human embryonic stem cells and bone marrow. , 2015, Tissue engineering. Part A.

[5]  A. Higuchi,et al.  Generation of pluripotent stem cells without the use of genetic material , 2015, Laboratory Investigation.

[6]  N. Terada,et al.  A practical guide to induced pluripotent stem cell research using patient samples , 2015, Laboratory Investigation.

[7]  Nicholas A. Kouris,et al.  Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties. , 2014, Stem cells and development.

[8]  R. McKay,et al.  Directed Differentiation of Human Induced Pluripotent Stem Cells Toward Bone and Cartilage: In Vitro Versus In Vivo Assays , 2014, Stem cells translational medicine.

[9]  A. Asakura.  Grand challenges in the field of stem cell research , 2014, Front. Cell Dev. Biol..

[10]  E. Wolvetang,et al.  Small Molecule Mesengenic Induction of Human Induced Pluripotent Stem Cells to Generate Mesenchymal Stem/Stromal Cells , 2012, Stem cells translational medicine.

[11]  H. Tsuji,et al.  Dystrophin conferral using human endothelium expressing HLA-E in the non-immunosuppressive murine model of Duchenne muscular dystrophy , 2010, Human molecular genetics.

[12]  S. Gojo,et al.  Plasticity of mesenchymal stem cells-regenerative medicine for diseased hearts- , 2003, Human Cell.

[13]  S. Takeda,et al.  Gene therapy for muscle disease. , 2010, Experimental cell research.

[14]  川道 弥生.  Cells of extraembryonic mesodermal origin confer human dystrophin in the mdx model of Duchenne muscular dystrophy , 2010 .

[15]  岡本 一真.  'Working' cardiomyocytes exhibiting plateau action potentials from human placenta-derived extraembryonic mesodermal cells , 2009 .

[16]  T. Okano,et al.  Novel Cardiac Precursor‐Like Cells from Human Menstrual Blood‐Derived Mesenchymal Cells , 2008, Stem cells.

[17]  P. Hematti,et al.  Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells. , 2008, Experimental hematology.

[18]  M. Toyoda,et al.  Myogenic transdifferentiation of menstrual blood-derived cells. , 2007, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[19]  S. Kyo,et al.  Menstrual blood-derived cells confer human dystrophin expression in the murine model of Duchenne muscular dystrophy via cell fusion and myogenic transdifferentiation. , 2007, Molecular biology of the cell.

[20]  T. Kiyono,et al.  Combination of hTERT and bmi-1, E6, or E7 Induces Prolongation of the Life Span of Bone Marrow Stromal Cells from an Elderly Donor without Affecting Their Neurogenic Potential , 2005, Molecular and Cellular Biology.

[21]  N. Socci,et al.  Derivation of Multipotent Mesenchymal Precursors from Human Embryonic Stem Cells , 2005, PLoS medicine.

[22]  T. Kiyono,et al.  Immortalization of human fetal cells: the life span of umbilical cord blood-derived cells can be prolonged without manipulating p16INK4a/RB braking pathway. , 2005, Molecular biology of the cell.

[23]  J Kohyama,et al.  Brain from bone: efficient "meta-differentiation" of marrow stroma-derived mature osteoblasts to neurons with Noggin or a demethylating agent. , 2001, Differentiation; research in biological diversity.

[24]  K. Segawa,et al.  Multipotent marrow stromal cell line is able to induce hematopoiesis in vivo , 1992, Journal of cellular physiology.